Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CASP3 | P42574 | 2/20 | 0.65 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.65 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.65 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | VCP | P55072 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25168239 | 0.90 | CYP19A1 (0.72) | NPC1RAB9AKDM4EMAPTMEN1 | |
| SCHEMBL7951268 | 0.83 | CDK5 (0.54) | NPC1RAB9AKDM4EMAPTMEN1 | |
| SCHEMBL1919663 | 0.82 | CYP19A1 (0.62) | NPC1RAB9AKDM4EMAPTMEN1 | |
| SCHEMBL29482430 | 0.82 | CYP19A1 (0.62) | NPC1RAB9AKDM4EMAPTMEN1 | |
| SCHEMBL1606850 | 0.82 | CYP19A1 (0.62) | NPC1RAB9AKDM4EMAPTMEN1 | |
| SCHEMBL4247549 | 0.82 | CYP19A1 (0.62) | NPC1RAB9AKDM4EMAPTMEN1 | |
| SCHEMBL1606452 | 0.82 | CYP19A1 (0.62) | NPC1RAB9AKDM4EMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL5534558 | 0.81 | CYP19A1 (0.60) | NPC1RAB9AKDM4EMAPTMEN1 | |
| SCHEMBL4892343 | 0.79 | NPC1 (0.69) | NPC1RAB9AKDM4EMAPTMEN1 | |
| SCHEMBL30048239 | 0.79 | NPC1 (0.69) | NPC1RAB9AKDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958850-B2 | Heteroaryl compounds for kinase inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| US-20230102829-A1 | Heteroaryl Compounds For Kinase Inhibition | ARIAD PHARMACEUTICALS, INC. | 2023-03-30 | — | — | US | disclosed |
| CN-110526912-B | Heteroaryl compounds for kinase inhibition | 武田药品工业株式会社 | 2023-02-14 | — | — | CN | disclosed |
| EP-3778584-A1 | PRODUCTION PROCESS OF 2-CHLORO-4-HETEROARYL-PYRIMIDINE DERIVATIVES | ARIAD Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778584-A1 | PRODUCTION PROCESS OF 2-CHLORO-4-HETEROARYL-PYRIMIDINE DERIVATIVES | ARIAD Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3409669-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3409669-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20190218212-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-20190218212-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-10227342-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-8030334-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| US-8030334-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| CN-102076665-A | Organic compounds | NOVARTIS AG | 2011-05-25 | — | — | CN | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| WO-2009156462-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218212-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | NPC1 1195/4885RAB9A 963/4885KDM4E 3491/4885 |
| US-20110082129-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | NPC1 142/4885RAB9A 4325/4885KDM4E 3921/4885 |
| US-20100261698-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | NPC1 142/4885RAB9A 4325/4885KDM4E 3921/4885 |
| US-11958850-B2 | Heteroaryl compounds for kinase inhibition | ERBB2, EGFR, ERBB3 | NPC1 1195/4885RAB9A 963/4885KDM4E 3491/4885 |
| US-10227342-B2 | Heteroaryl compounds for kinase inhibition | ERBB2, EGFR, ERBB3 | NPC1 1195/4885RAB9A 963/4885KDM4E 3491/4885 |
| US-20230102829-A1 | Heteroaryl Compounds For Kinase Inhibition | ERBB2, EGFR, ERBB3 | NPC1 1195/4885RAB9A 963/4885KDM4E 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.